This is a fair and important question before starting any treatment. Is enclomiphene FDA approved? No, it is not, and understanding the full regulatory history explains exactly why, along with what this status actually means for you as a patient in 2026.
The Direct Answer
As of the most current regulatory information available, no FDA approved enclomiphene product exists for any indication. This has been the case since the medication was first developed, despite multiple serious attempts to gain approval over more than a decade.
The Company Behind the Original Approval Attempt
Enclomiphene’s regulatory journey began with a company called Repros Therapeutics, a Houston based biopharmaceutical company that developed enclomiphene citrate under the brand name Androxal specifically for treating secondary hypogonadism in men.
This was a genuine, well funded pharmaceutical development effort, not an obscure or fringe project. Repros pursued formal FDA approval through the standard New Drug Application process multiple times.
The Three Failed Approval Attempts
The regulatory history spans nearly a decade of submissions and rejections. Repros filed its initial New Drug Application in late 2009. The FDA issued a Complete Response Letter in 2010, citing problems with the bioanalytical assay used to measure enclomiphene and zuclomiphene plasma concentrations in key pharmacokinetic studies.
This was the first of three separate NDA submissions between 2009 and 2015, all of which received Complete Response Letters from the FDA rather than approval.
Why the Final Attempt Failed in 2015
The most detailed rejection came with the final submission. In December 2015, the FDA issued a Complete Response Letter stating that based on recent scientific developments, the design of the enclomiphene Phase 3 studies was no longer adequate to demonstrate clinical benefit, and recommended that an additional Phase 3 study be conducted to support approval.
The FDA also noted specific concerns regarding study entry criteria, dosage titration methodology, and bioanalytical method validation across the Phase 3 program. These were not concerns about safety data showing harm. They were concerns about whether the study design proved sufficient clinical benefit to justify approval.
An Important Distinction: Rejection Is Not the Same as Unsafe
This point deserves emphasis, since it is often misunderstood. A Complete Response Letter does not necessarily mean a drug is unsafe. It indicates that the FDA requires more robust evidence before granting approval.
In enclomiphene’s case, the FDA determined the clinical trial data were not sufficient to prove a clear enough benefit, not that the medication demonstrated harm. This distinction matters significantly for understanding the current regulatory landscape.
Why the Additional Studies Were Never Completed
After the 2015 rejection, the path forward required additional Phase 3 trials. However, these studies were never completed, possibly related to corporate changes after Allergan acquired Repros Therapeutics in 2017.
The development of enclomiphene under the Androxal brand was ultimately discontinued in 2021. This halt in development means it is unlikely to be submitted for FDA approval again in the near future, cementing its current status as an investigational medication available only through specific channels.
What Happened in Europe
The regulatory story extends beyond the United States. By December 2016, enclomiphene was in preregistration and under review by both the FDA and the European Medicines Agency. In January 2018, the European regulatory committee recommended refusal of marketing authorization for enclomiphene specifically for secondary hypogonadism.
This means the medication faced similar regulatory hurdles on both sides of the Atlantic, reinforcing that the underlying issue was about study design and demonstrated clinical benefit rather than a single regulatory body’s isolated decision.
Current Regulatory Status Summary
| Regulatory Question | Current Answer |
|---|---|
| Is enclomiphene FDA approved? | No, for any indication |
| Brand name attempted | Androxal, developed by Repros Therapeutics |
| Number of NDA submissions | Three attempts between 2009 and 2015 |
| Outcome of each submission | Complete Response Letter, no approval |
| Development status | Discontinued in 2021 |
| European regulatory outcome | Marketing authorization refused in 2018 |
| Current legal access | Compounding pharmacies only, by prescription |
How This Affects Legal Access Today
Despite lacking FDA approval, there remains a legitimate legal pathway to access enclomiphene. Licensed physicians can prescribe it off label, and these prescriptions can be legally filled by state licensed compounding pharmacies. Compounding is the process where a pharmacist creates a personalized medication for an individual patient under regulated conditions.
This is meaningfully different from purchasing unregulated research chemicals online, which carry real risks around purity and accurate dosing that compounded medications from licensed pharmacies do not.
The 2022 Compounding Complication
Beyond the FDA approval issue itself, enclomiphene faces an additional regulatory layer. Enclomiphene remains excluded from the 503A Bulks List, which defines the bulk substances permitted for compounding under federal law, following a 2022 Pharmacy Compounding Advisory Committee vote against its inclusion.
Enclomiphene citrate remains in a category described as under evaluation as of the most recent FDA updates, meaning its compounding status remains unsettled even though pharmacies continue to legally fulfill prescriptions in the meantime.
Why This Matters for Your Treatment Decision
Understanding this full regulatory history helps set accurate expectations. Because it is not FDA approved and long term data remain limited, decisions about enclomiphene should always be made with a qualified healthcare provider who can evaluate your individual medical needs and monitor treatment appropriately.
This is not a reason to avoid treatment altogether. Many effective medications are prescribed off label for legitimate medical reasons. It is a reason to work specifically with an experienced provider and a properly licensed compounding pharmacy rather than an unverified source. The book-appointment page connects you with this kind of properly structured care.
What the Clinical Evidence Still Shows Despite Non Approval
It is worth remembering that lack of FDA approval does not erase the clinical trial data that does exist. A key trial result showed enclomiphene normalized testosterone in seventy three percent of treated men, compared to under thirty seven percent on placebo, a substantial and statistically meaningful difference.
The underlying biological effectiveness is well documented. What remains unresolved is the specific regulatory pathway required for formal approval, which stalled due to study design issues rather than a demonstrated lack of efficacy or safety concern.
Pricing Given the Current Regulatory Landscape
Since enclomiphene is only available through compounding pharmacies rather than standard retail pharmacies, typical costs run eighty to two hundred dollars per month depending on dosage and provider.
This reflects the compounding process itself rather than any premium tied to regulatory status. The FAQs page covers more on typical program costs.
The Bottom Line
Is enclomiphene FDA approved? No, despite three separate attempts by its original developer between 2009 and 2015, all of which ended in Complete Response Letters citing study design concerns rather than safety failures.
Development was ultimately discontinued in 2021, making future approval unlikely in the near term. Despite this, enclomiphene remains legally accessible through licensed physicians and compounding pharmacies, and the underlying clinical evidence for its effectiveness remains substantial.
Working with an experienced provider matters more given this regulatory context, not less. Learn more about how this shapes the treatment approach on the about-us page.
Frequently Asked Questions
Is enclomiphene FDA approved for any use?
No, no FDA approved enclomiphene product exists for any indication as of the current regulatory status.
Why did enclomiphene fail to get FDA approval?
The FDA determined the submitted Phase 3 study designs were not adequate to demonstrate clear clinical benefit, requesting additional trials that were never completed.
Does lack of FDA approval mean enclomiphene is unsafe?
No, a Complete Response Letter reflects concerns about study design and demonstrated benefit, not necessarily safety failures.
Is it still legal to get a prescription for enclomiphene?
Yes, licensed physicians can prescribe it off label, filled through licensed compounding pharmacies.
Will enclomiphene ever get FDA approved in the future?
Development under the Androxal brand was discontinued in 2021, making near term approval unlikely.
What happened with enclomiphene in Europe?
The European Medicines Agency recommended refusal of marketing authorization for the same indication in 2018.
